banner image

News & Events

Stay up to date with latest activity at SHIL

Spotlight on... Aurum Biosciences

Spotlight on... Aurum Biosciences image

SHIL has a strong record in producing spin-out companies on behalf of NHS Scotland. Each company has been set up to produce and market healthcare innovations that originated from NHS Scotland employees.

This month we shine the spotlight on Aurum Biosciences Ltd a 2015 spin-out company of SHIL, NHS Greater Glasgow and Clyde and the University of Glasgow who are preparing to showcase their innovative stroke technology at BIO2018 – the world’s largest pharma and biotech partnering event taking place in Boston in early June.

Using technology originally developed within the Institute of Neuroscience & Psychology at the University of Glasgow and NHS Greater Glasgow and Clyde, Aurum Biosciences develops novel pharmaceuticals for use in a number of different clinical indications of high unmet medical need. Its innovative ABL-101 stroke technology is a first-in-class stroke therapy and diagnostic and recently received UK regulatory approval (MHRA) for a Phase 2 clinical trial due to start in Q1 2018.

As the second biggest killer worldwide - one in six people having a stroke by the age of 75, someone has a stroke worldwide every two seconds and approximately 100,000 people a year suffer from a stroke in the UK alone – that is around one stroke every five minutes (State of the Nation – Stroke Statistics, February 2018). ABL101 is the first major advancement in the management of all acute ischaemic stroke patients in the past 20 years and has the potential to save and improve thousands of lives around the world. 

So how does it work? Dr David Brennan, Director of Project Management at Aurum Biosciences explains:

Aurum strives to provide healthcare improvements worldwide, resulting in significant societal benefits at both the patient and healthcare provider level and is an exemplar of the talent, vision and dedication of health professionals across Scotland. With follow-on programmes including products for heart disease, cancer, epilepsy, and dementia, it has the potential to drive significant life-saving benefits across each of these areas.

Read more

Back to Blog